Business
Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026
Abstract presenting 48-week IMPACT Phase 2b efficacy and safety data selected for inclusion in “Best of EASL 2026” by EASL Oral presentation will highlight further the 48-week IMPACT efficacy and safety data Late-breaker abstract featuring new digital pathology analysis of liver fibrosis regression from IMPACT 24-week data GAITHERSBURG, Md., May 13, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious li
About this update from Altimmune, Inc.
[{"type":"image","alt":"Altimmune, Inc","displaySize":"","headline":null,"caption":"Altimmune, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":82,"url":"https://media.zenfs.com/en/globenewswire.com/767e25bad8979b96701d6a099286a009"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/JlCBPB8gl64kWThcosrPtw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTExNQ--/https://media.zenfs.com/en/globenewswire.com/767e25bad8979b96701d6a099286a009","width":150,"height":82},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/JlCBPB8gl64kWThcosrPtw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTExNQ--/https://media.zenfs.com/en/globenewswire.com/767e25bad8979b96701d6a099286a009","width":150,"height":82}},"lazy":false},{"type":"text","content":"Abstract presenting 48-week IMPACT Phase 2b efficacy and safety data selected for inclusion in “Best of EASL 2026” by EASL","length":122,"tagName":"p"},{"type":"text","content":"Oral presentation will highlight further the 48-week IMPACT efficacy and safety data ","length":84,"tagName":"p"},{"type":"text","content":"Late-breaker abstract featuring new digital pathology analysis of liver fibrosis regression from IMPACT 24-week data","length":116,"tagName":"p"},{"type":"text","content":"GAITHERSBURG, Md., May 13, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that analyses of data from its IMPACT Phase 2b clinical trial in metabolic dysfunction-associated steatohepatitis (MASH) will be presented at the European Association for the Study of the Liver (EASL) Congress 2026, taking place May 27-30 in Barcelona, Spain.","length":464,"tagName":"p"},{"type":"text","content":"Data will be featured in both an oral presentation and several poster sessions, including a late-breaking poster presentation. The company also announced that its abstract on 48-week results has been selected by EASL as Best of EASL 2026 in their summary deck for its noteworthy contribution to the scientific program of the EASL congress.","length":339,"tagName":"p"},{"type":"text","content":"The oral presentation will showcase 48-week efficacy and safety results from the IMPACT Phase 2 trial, while additional poster presentations will focus on new 24-week findings, including digital pathology analysis of fibrosis regre...